Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • ID/Cancers
    Oncology...
    December 18, 2017

    Novel approaches to adjuvant therapies for Stage III or IV melanoma prove successful

    READ
  • GI/Kidneys
    Gastroenterology...
    December 18, 2017

    Gastric cancer risk increased with long-term PPI use

    READ
  • GI/Kidneys
    Gastroenterology...
    December 12, 2017

    Choice of bowel preparation for colonoscopy affects outcomes

    READ
  • Self-care
    OTC Medicines Corner...
    December 12, 2017

    Long-term use of acetaminophen during pregnancy associated with...

    READ
  • Personalized Care
    Drug Interactio...
    December 4, 2017

    Drug interactions with newer oral anticoagulants are a concern

    READ
  • Heart/Lungs
    Focus on Lipids Care...
    December 4, 2017

    Statins are associated with development of diabetes in a high-...

    READ
  • Endocrine/Rheum
    Endocrinology...
    November 28, 2017

    Long-term bisphosphonate use associated with higher fracture risk

    READ
  • Self-care
    OTC Medicines Corner...
    November 28, 2017

    Unique dosing regimen may result in better iron absorption

    READ
  • Personalized Care
    Pharmacogenomic...
    November 20, 2017

    Genotype-guided warfarin dosing resulted in better outcomes in...

    READ
  • Self-care
    OTC Medicines Corner...
    November 20, 2017

    Stopping low-dose aspirin may increase risk of cardiovascular...

    READ
  • Neuro/Psych
    Psychiatry...
    November 14, 2017

    Prolonged-release melatonin effective for sleep disturbances in...

    READ
  • Read more about Novel topical antibiotic approved for impetigo
  • Read more about New biosimilar of infliximab approved for multiple indications
  • Read more about FDA approves generic versions of sildenafil
  • Read more about Evolocumab now approved to prevent heart attack and stroke
  • Read more about Novel approaches to adjuvant therapies for Stage III or IV melanoma prove successful
  • Read more about Gastric cancer risk increased with long-term PPI use
  • Read more about New indication approved for treatment of eosinophilic granulomatosis with polyangiitis
  • Read more about First nebulized LAMA approved for treatment of COPD in the United States
  • Read more about FDA approves the first short-acting "follow-on" insulin product to treat diabetes
  • Read more about Choice of bowel preparation for colonoscopy affects outcomes

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Medication Monitor

NEW DRUG APPROVALS

  • December 19, 2017
    Ozenoxacin cream, 1%
    (Xepi):
    Novel topical antibiotic approved for impetigo
  • December 12, 2017
    Insulin lispro injection
    (Admelog):
    FDA approves the first short-acting "follow-on" insulin product to treat diabetes
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • December 19, 2017
    Infliximab-qbtx
    (Ixifi):
    New biosimilar of infliximab approved for multiple indications
  • December 19, 2017
    Sildenafil
    (Viagra):
    FDA approves generic versions of sildenafil
See more Supplemental Approvals

ALERTS AND RECALLS

  • November 29, 2017
    Biotin (Vitamin B7)
    (Multiple trade names):
    FDA warns that biotin may interfere with lab tests, cause adverse events
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • June 13, 2017
    Oxymorphone hydrochloride
    (Reformulated Opana ER):
    FDA requests removal of Opana ER for risks related to abuse
See more Product withdrawals


                                

Editor's Picks

  • Novel approaches to adjuvant therapies for Stage...
  • Gastric cancer risk increased with long-term PPI...
  • Choice of bowel preparation for colonoscopy...
  • Long-term use of acetaminophen during pregnancy...
  • Drug interactions with newer oral anticoagulants...

Popular Articles

  • AHA releases guidance on statin drug interactions...
  • The Joint Commission releases new antimicrobial...
  • Fewer CV events observed in patients with...
  • Extended anticoagulation with rivaroxaban...
  • Long-term oxygen use not beneficial in some...

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy